Skip to main content

The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials

International Urology and Nephrology volume 46, pages 275–284 (2014)Cite this article

Abstract

Purpose

Mirabegron, a potent and selective β3-adrenoceptor agonist, has been developed for the treatment of overactive bladder (OAB). We carried out a systematic review and meta-analysis to assess the efficacy and safety of the drug for treating OAB.

Methods

A literature review was performed to identify all published randomized double-blind, placebo-controlled phase III trials of mirabegron for the treatment of OAB. The search included the following databases: MEDLINE, EMBASE and the Cochrane Controlled Trials Register. The reference lists of the retrieved studies were also investigated. A systematic review and meta-analysis of phase III trials were conducted.

Results

Four publications involving a total of 5,761 patients were used in the analysis, including four phase III RCTs that compared mirabegron with placebo. We found that mirabegron was effective in treating OAB in our meta-analysis. Co-primary efficacy end points: the mean number of incontinence episodes per 24 h (the standardized mean difference (SMD) = −0.44, 95 % confidence interval (CI) −0.59 to −0.29, p < 0.00001); the mean number of micturitions per 24 h (SMD = −0.62, 95 % CI −0.80 to −0.45, p < 0.00001) and key secondary efficacy end points: mean volume voided per micturition; mean number of urgency episodes per 24 h indicated that mirabegron was more effective than the placebo. Safety assessments included common treatment-emergent adverse events (TEAEs) [OR 1.10, 95 % CI 0.93–1.31, p = 0.25), hypertension, cardiac arrhythmia TEAEs, urinary retention and discontinuations due to adverse event indicated that mirabegron was well tolerated.

Conclusions

This meta-analysis indicates that mirabegron to be an effective and safe treatment for OAB symptoms with a low occurrence of side effects. It offers promise as an effective oral agent for the treatment of OAB with a distinct efficacy/tolerability balance.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5

References

  1. Abrams P, Cardozo L, Fall M et al (2002) The standardisation of terminology of lower urinary tract function: report from the standardisation subcommittee of the international continence society. Neurourol Urodyn 21:167–178

    PubMed  Article  Google Scholar 

  2. Irwin D, Milsom I, Hunskaar S et al (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306–1314

    PubMed  Article  Google Scholar 

  3. Sacco E, Tienforti D, D’Addessi A et al (2010) Social, economic, and health utility considerations in the treatment of overactive bladder. J Urol 2:11–24

    CAS  Google Scholar 

  4. Chapple CR (2000) Muscarinic receptor antagonists in the treatment of overactive bladder. Urology 55:33

    CAS  PubMed  Article  Google Scholar 

  5. Garely AD, Borrows LJ (2002) Current pharmacotherapeutic strategies for overactive bladder. Expert Opin Pharmacother 3:827

    CAS  PubMed  Article  Google Scholar 

  6. Abrams P, Andersson KE, Buccafusco JJ et al (2006) Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladder. Br J Pharmacol 148:565–578

    CAS  PubMed  Article  Google Scholar 

  7. D’Souza AO, Smith MJ, Miller LA et al (2008) Persistence, adherence, and switch rates among extended-release and immedia terelease overactive bladder medications in a regional managed care plan. J Manag Care Pharm 14:291–301

    PubMed  Google Scholar 

  8. Benner JS, Nichol MB, Rovner ES et al (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105:1276–1282

    PubMed  Article  Google Scholar 

  9. Takasu T, Ukai M, Sato S et al (2007) Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-[(2-hydroxy-2-phenyl-ethyl)amino]ethyl} acetanilide (YM178), a novel selective beta3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642

    CAS  PubMed  Article  Google Scholar 

  10. Takeda M, Obara K, Mizusawa T et al (1999) Evidence for beta3-adrenoceptor subtypes in relaxation of the human urinary bladder detrusor: analysis by molecular biological and pharmacological methods. J Pharmacol Exp Ther 288:1367–1373

    CAS  PubMed  Google Scholar 

  11. Igawa Y, Aizawa N, Homma Y (2010) Beta3-adrenoceptor agonists: possible role in the treatment of overactive bladder. Korean J Urol 51:811–818

    PubMed Central  PubMed  Article  Google Scholar 

  12. Andersson K, Chapple C, Cardozo L et al (2009) Pharmacological treatment of urinary incontinence. In: Abrams P, Cardozo L, Khoury S, Wein A (eds) Incontinence, 4th international consultation on incontinence. Plymbridge Distributors, Plymouth, pp 631–699

    Google Scholar 

  13. Andersson K, Arner A (2004) Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 84:935–986

    CAS  PubMed  Article  Google Scholar 

  14. Otsuka A, Shinbo H, Matsumoto R et al (2008) Expression and functional role of beta-adrenoceptors in the human urinary bladder urothelium. Naunyn Schmiedebergs Arch Pharmacol 377:473–481

    CAS  PubMed  Article  Google Scholar 

  15. Limberg B, Andersson K, Aura KF et al (2010) β-Adrenergic receptor subtype expression in myocyte and non-myocyte cells in human female bladder. Cell Tissue Res 342:295–306

    CAS  PubMed Central  PubMed  Article  Google Scholar 

  16. Jadad AR (1998) Randomised controlled trials. BMJ, London

    Google Scholar 

  17. Higgins JPT, Green S (eds) (2011) Cochrane handbook for systematic reviews of interventions, v.5.1. Cochrane collaboration web site. http://www.cochrane-handbook.org/

  18. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177–188

    CAS  PubMed  Article  Google Scholar 

  19. Higgins JP, Thompson SG, Deeks JJ et al (2003) Measuring inconsistency in meta-analyses. BMJ 327:557–560

    PubMed  Article  Google Scholar 

  20. Khullar V, Amarenco G, Angulo JC et al (2013) Efficacy and tolerability of mirabegron, a β (3)-adrenoceptor agonist, in patients with overactive bladder: results from a randomised European–Australian phase 3 trial. Eur Urol 63(2):283

    CAS  PubMed  Article  Google Scholar 

  21. Nitti VW, Auerbach S, Martin N et al (2013) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189:1388

    CAS  PubMed  Article  Google Scholar 

  22. Van KP, Barkin J, Castro-Diaz D et al (2013) Randomised, double-blind, placebo-controlled phase III study to assess the efficacy and safety of mirabegron 25 mg and 50 mg once daily in overactive bladder (OAB). In: Presented at the international continence society meeting, Beijing, China, 2012. Available at http://www.icsoffice.org/Abstracts/Publish/134/000359.pdf. Accessed 17 Feb 2013

  23. Edwards SJ, Karner C, Trevor N et al (2013) Mirabegron for the treatment of symptoms associated with overactive bladder. BMJ-TAG, London

    Google Scholar 

  24. Chapple CR, Kaplan SA, Mitcheson D et al (2013) Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β(3)-adrenoceptor agonist, in overactive bladder. Eur Urol 63(2):296

    CAS  PubMed  Article  Google Scholar 

  25. Wagg A, Compion G, Fahey A et al (2012) Persistence with prescribed antimuscarinic therapy for overactive bladder: a UK experience. BJU Int. doi:10.1111/j.1464-410X.2012.11023.x

    PubMed  Google Scholar 

  26. Linner L, Schioler H, Samuelsson E et al (2011) Low persistence of anticholinergic drug use in Sweden. Eur J Clin Pharmacol 67:535–536

    PubMed  Article  Google Scholar 

  27. Yamanishi T, Chapple CR, Yasuda K et al (2003) Role of beta-adrenoceptor subtypes in mediating relaxation of the pig bladder trigonal muscle in vitro. Neurourol Urodyn 22:338

    CAS  PubMed  Article  Google Scholar 

Download references

Conflict of interest

The authors had no conflicts of interest to declare in relation to this article.

Author information

Affiliations

  1. Department of Urology, Beijing Tian-Tan Hospital, Capital Medical University, No. 6 Tiantan Xi Li, Dongcheng District, Beijing, 100050, China

    Yuanshan Cui, Huantao Zong, Chenchen Yang, Huilei Yan & Yong Zhang

Authors
  1. Yuanshan Cui
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Huantao Zong
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chenchen Yang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Huilei Yan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yong Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yong Zhang.

Additional information

Huantao Zong is the co-first author.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Cui, Y., Zong, H., Yang, C. et al. The efficacy and safety of mirabegron in treating OAB: a systematic review and meta-analysis of phase III trials. Int Urol Nephrol 46, 275–284 (2014). https://doi.org/10.1007/s11255-013-0509-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-013-0509-9

Keywords

  • Mirabegron
  • Overactive bladder
  • Meta-analysis
  • Randomized controlled phase III trial